文献速递肾移植

供体尿液生物标志物联合KDPI预测 deceased donor 移植肾功能

Donor Urinary Biomarkers and the Prediction of Deceased Donor Allograft Function.
PubMed 文献 · J Am Soc Nephrol · 2026-07-09

本研究纳入2010-2013年来自同一供体的配对肾移植受者,随访3年,评估供体尿液生物标志物(uromodulin、osteopontin、CHI3L1)联合KDPI对一致良好或不良结局的预测能力。结果显示联合生物标志物较单用KDPI提高判别能力,免疫assay和侧向流设备均一致。

要点

  • 供体尿液生物标志物联合KDPI可提高预测配对肾移植结局的判别力。
  • 联合标志物为供肾质量评估提供额外信息,有助分配决策。
  • 免疫assay与即时侧向流设备测定的改善趋势一致。

核心结论

  • 供体尿液生物标志物联合KDPI可改善对配对肾移植一致结局的预测,且两种检测平台均观察到较单用KDPI的提升。

研究设计与样本

  • 研究随访2010-2013年来自同一供体的配对肾移植受者3年,肾脏取自五个器官获取组织。
  • 共识别474名双肾均移植的供体,其中一致良好结局438例(92%),一致不良结局36例(8%)。

主要发现

  • 区分一致良好与一致不良结局,单用KDPI的AUC为0.80(SE 0.04)。
  • 免疫assay测定的KDPI联合uromodulin、osteopontin和chitinase-3-like protein 1的AUC为0.86(SE 0.03)。
  • 在105名供体侧向流设备测定亚组中,KDPI联合三种生物标志物的AUC为0.85(SE 0.04),单用KDPI为0.81(SE 0.05)。

关键数值与推荐

  • 一致良好结局定义为移植后3年两名受者eGFR均≥45 ml/min per 1.73 m²。
  • 一致不良结局定义为两名受者均发生移植物失败(返回透析或等待名单)或eGFR<20 ml/min per 1.73 m²。

临床怎么用

  • 在肾移植分配中,可考虑将供体尿液生物标志物与KDPI联合用于评估供肾质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Combining donor urinary biomarkers with Kidney Donor Profile Index improved the ability to predict paired recipient outcomes. Donor urinary biomarkers provided additional information on donor kidney quality, thus informing the kidney transplant allocation process. BACKGROUND: Kidney transplant allocation currently relies on the Kidney Donor Profile Index (KDPI), a measure that has limitations. This study evaluated the potential of using KDPI and deceased donor urinary biomarkers to improve the assessment of organ quality and the prediction of allograft outcomes compared with KDPI alone. METHODS: Pairs of kidney recipients from the same donor transplanted between 2010 and 2013 were followed for 3 years post-transplant from kidneys procured at five organ procurement organizations. By 3 years post-transplant, concordant good outcomes were defined as both recipients having an eGFR ≥45 ml/min per 1.73 m 2 , while concordant poor outcomes were defined as both recipients experiencing graft failure (return to dialysis or waitlisted) or having an eGFR <20 ml/min per 1.73 m 2 . Urinary biomarkers (uromodulin, osteopontin, and chitinase-3-like protein 1) were measured by immunoassay using a MesoScale Device in all donors and by lateral flow devices in a subset. Discriminatory ability was quantified with the area under the receiver operator characteristics curve (AUC). RESULTS: We identified 474 donors with both kidneys transplanted and either concordant good outcomes (438; 92%) or concordant poor outcomes (36; 8%). For distinguishing concordant good from concordant poor outcomes, the AUC for KDPI alone was 0.80 (SE 0.04); the AUC for KDPI combined with uromodulin, osteopontin, and chitinase-3-like protein 1 measured by immunoassay was 0.86 (SE 0.03). In a subset of 105 donors with lateral flow device measurements, the AUC for KDPI plus three biomarkers was 0.85 (SE 0.04), compared with 0.81 (SE 0.05) for KDPI alone. CONCLUSIONS: Combining donor urinary biomarkers with KDPI improved prediction of concordant allograft outcomes, regardless of assay platform. The improvement over KDPI alone was observed both with immunoassay and with point-of-care lateral flow device measurements.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Thiessen Philbrook H, Kerr KF, Mohan S, et al. Donor Urinary Biomarkers and the Prediction of Deceased Donor Allograft Function. J Am Soc Nephrol. 2026. PMID: 42424130. doi:10.1681/ASN.0000001183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。